Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on March 2, 2026. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of February 28, 2026, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial results report.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely updates the share capital structure as of the reporting date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the share count for shareholder notification purposes.
Important Facts for Investors
- Issued Share Capital: As of February 28, 2026, GSK plc had 4,316,162,488 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 244,027,094 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,072,135,394.
- Shareholder Notification: This voting rights figure serves as the denominator for shareholders calculating their interest thresholds under FCA rules.
- Contact: Notifications regarding share interests should be sent to company.secretary@gsk.com.